a Comparive Study of Ketamine-Propofol Versus Dexmedetomidine-Propofol Sedation in Pediatric Patients Undergoing Cardiac Catheterization for Device Closure of Simple Left-to-right Shunts
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Cairo、埃及
- 招聘中
- Ain Shams University Hospital
-
接触:
- Noha Tarek Hassan
- 电话号码:01000667030
- 邮箱:Noha.Hassan@med.asu.edu.eg
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
接受健康志愿者
描述
Inclusion Criteria:
- Age 2-12 years, male or female
- Weight ≥ 10 kg
- Scheduled for elective transcatheter device closure of a simple left-to-right shunt, including:
- Secundum atrial septal defect (ASD) suitable for device closure
- Small muscular ventricular septal defect (VSD) eligible for percutaneous device closure
- Patent ductus arteriosus (PDA) closure
- Procedure performed with transthoracic or transesophageal echocardiographic guidance according to the cardiology team's practice
- ASA physical status II-III
- Written informed consent obtained from a parent or legal guardian
Exclusion Criteria:
- Cyanotic congenital heart disease
- Complex congenital cardiac lesions
- Risk of pulmonary hypertensive crisis
- Requirement for general anesthesia and cuffed endotracheal tube at the discretion of the cardiology or anesthesia team
- Baseline oxygen requirement > 2 L/min
- Use of noninvasive ventilation
- Known allergy or intolerance to ketamine, dexmedetomidine, or propofol
- Significant hepatic impairment
- Significant renal impairment
- Advanced atrioventricular block
- Clinically significant bradyarrhythmia
- Uncontrolled epilepsy
- Raised intracranial pressure
- Severe obstructive sleep apnea
- Craniofacial anomalies associated with anticipated difficult airway management
- BMI > 97th percentile when judged to confer high risk of sedation-related airway obstruction
- Current beta-blocker use
- Current clonidine use
- Acute upper respiratory tract infection within 2 weeks before the procedure
- Emergency or add-on procedures
- Anticipated procedure duration < 20 minutes
- Anticipated procedure duration > 3 hours
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Group KP: Ketamine + Propofol.
Group that will receive Propofol and ketamine
|
Ketamine IV bolus 1 mg/kg (range commonly 0.5-1.5 mg/kg) administered as an initial bolus to provide analgesia and hemodynamic support; followed by a propofol infusion 100-150 µg/kg/min (titrated to clinical effect). Rescue propofol boluses 0.5 mg/kg IV may be given for inadequate sedation
其他名称:
|
|
有源比较器:Group DP: Dexmedetomidine + Propofol
Group that will receive Dexmedetomidine and Propofol
|
Dexmedetomidine loading dose 1 µg/kg over 10 minutes (range 0.5-1 µg/kg reported) followed by maintenance infusion per clinical need; co-administration of propofol infusion 100-150 µg/kg/min, titrated to the sedation target. Rescue propofol boluses 0.5 mg/kg IV may be used for breakthrough movement or inadequate sedation
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of respiratory complications
大体时间:2 hours
|
Percentage of participants experiencing one or more respiratory complications (apnea, hypoxemia, atelectasis, hypercapnia, or need for advanced airway management) during the study period.
|
2 hours
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mean Heart Rate
大体时间:2 hours
|
Heart rate (bpm) measured during the procedure and recovery period.
|
2 hours
|
|
Mean Arterial Pressure
大体时间:2 hours
|
Mean arterial pressure ( mmHg) measured during the procedure and recovery period.
|
2 hours
|
|
Recovery time
大体时间:2 hours
|
Time from discontinuation of sedative administration to achievement of discharge readiness based on the institution's recovery criteria.
|
2 hours
|
|
Adequate Sedation rate
大体时间:2 hours
|
Percentage of participants achieving the target level of sedation throughout the procedure without requiring a change in the assigned sedation regimen.
|
2 hours
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.